Registration guide - Union Product Database (UPD) for veterinary medicinal products

Human medicines European public assessment report (EPAR): Zavicefta, ceftazidime,avibactam, Pneumonia, Bacterial;Soft Tissue Infections;Pneumonia;Urinary Tract Infections;Gram-Negative Bacterial Infections, Date of authorisation: 23/06/2016, Revision: 15, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Lidocaine (hydrochloride monohydrate), decision type: , therapeutic area: , PIP number: P/0419/2022

Opinion/decision on a Paediatric investigation plan (PIP): 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole, decision type: , therapeutic area: , PIP number: P/0420/2022

Human medicines European public assessment report (EPAR): Synjardy, empagliflozin,metformin, Diabetes Mellitus, Type 2, Date of authorisation: 27/05/2015, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Glyxambi, empagliflozin,linagliptin, Diabetes Mellitus, Type 2, Date of authorisation: 11/11/2016, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Erleada, apalutamide, Prostatic Neoplasms, Date of authorisation: 14/01/2019, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Clopidogrel / Acetylsalicylic acid Mylan, clopidogrel,acetylsalicylic acid, Acute Coronary Syndrome;Myocardial Infarction, Date of authorisation: 09/01/2020, Revision: 5, Status: Authorised

Meeting of the CTTI/FDA Patient Engagement Collaborative (PEC) and EMA Patients and Consumers Working Party (PCWP), Online, from 20/07/2023 to 20/07/2023

Human medicines European public assessment report (EPAR): Eporatio, epoetin theta, Kidney Failure, Chronic;Anemia;Cancer, Date of authorisation: 29/10/2009, Revision: 13, Status: Authorised